Thompson Siegel & Walmsley LLC maintained its stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,125 shares of the medical equipment provider’s stock at the close of the second quarter. Thompson Siegel & Walmsley LLC’s holdings in Hologic were worth $187,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently made changes to their positions in HOLX. Strs Ohio increased its stake in Hologic by 11.0% during the 1st quarter. Strs Ohio now owns 28,657 shares of the medical equipment provider’s stock worth $1,219,000 after acquiring an additional 2,837 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Hologic by 10.4% in the 1st quarter. Russell Investments Group Ltd. now owns 321,371 shares of the medical equipment provider’s stock valued at $13,678,000 after purchasing an additional 30,190 shares during the last quarter. Sumitomo Mitsui Asset Management Company LTD increased its stake in shares of Hologic by 10.6% in the 1st quarter. Sumitomo Mitsui Asset Management Company LTD now owns 21,345 shares of the medical equipment provider’s stock valued at $908,000 after purchasing an additional 2,049 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in shares of Hologic by 15.2% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 29,166 shares of the medical equipment provider’s stock valued at $1,241,000 after purchasing an additional 3,843 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in shares of Hologic by 1.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 207,124 shares of the medical equipment provider’s stock valued at $8,806,000 after purchasing an additional 1,972 shares during the last quarter. Institutional investors own 96.39% of the company’s stock.
Hologic, Inc. (NASDAQ HOLX) traded down 0.05% on Friday, hitting $37.72. 3,344,455 shares of the stock traded hands. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80. The stock has a market cap of $10.58 billion, a price-to-earnings ratio of 14.05 and a beta of 0.92. The company’s 50 day moving average price is $38.90 and its 200-day moving average price is $42.58.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company’s revenue was up 12.4% compared to the same quarter last year. During the same period last year, the firm posted $0.51 earnings per share. On average, analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.
In other news, Director Elaine Ullian sold 8,849 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $45.28, for a total value of $400,682.72. Following the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at $1,078,116.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the firm’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,594 shares of company stock worth $1,168,871. Insiders own 0.79% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by BBNS and is the property of of BBNS. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://baseballnewssource.com/markets/thompson-siegel-walmsley-llc-maintains-stake-in-hologic-inc-holx/1611507.html.
HOLX has been the topic of several recent analyst reports. Royal Bank Of Canada cut their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a report on Thursday, August 3rd. BidaskClub lowered Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC decreased their target price on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $48.64.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with our FREE daily email newsletter.